Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Post by stockman6767on Aug 30, 2020 6:06pm
290 Views
Post# 31477340

Re: 35% efficacy is huuuuge

Re: 35% efficacy is huuuugeOK, let's grant the 35% survival rate which is great news for those in the hospital ICU. So LMNL will will collect  say a liter of blood plasma. they do not process this to extract antibodies or anything else. They are merely a collection center for blood. Then they resell the same unprocessed blood for transfusion at the ICU into the patients. How much of a mark up do you think they can charge for that liter of blood? This is a great humanitarian effort but totally meaningless in terms of the LMNL bottom line revenue. The small amount this will raise hardly moves the needle.
<< Previous
Bullboard Posts
Next >>